Back to top
more

Cardiff Oncology (CRDF)

(Delayed Data from NSDQ)

$4.07 USD

4.07
516,206

+0.08 (2.01%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.20 +0.13 (3.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CRDF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cardiff Oncology, Inc. [CRDF]

Reports for Purchase

Showing records 1 - 20 ( 27 total )

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/06/2024

Company Report

Pages: 5

Confirmatory 2L ONSEMBLE Trial Results; 2023 Financials; Raising PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/07/2023

Company Report

Pages: 4

All Eyes on Initial CRDF-004 Results in Mid-2024; 3Q23 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/27/2023

Company Report

Pages: 5

Onvansertib Yields Positive Early Pancreatic Cancer Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/11/2023

Company Report

Pages: 4

2Q23 Financial Results Reported; Modulating PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/08/2023

Company Report

Pages: 4

ONSEMBLE Trial Culled in Favor of 1L mCRC Trial in Partnership With Pfizer; Modulating PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/09/2023

Company Report

Pages: 4

1Q23 Financial Results; Lowering PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/29/2023

Company Report

Pages: 4

First Patient Dosed in Phase 2 ONSEMBLE Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/07/2023

Company Report

Pages: 4

Multiple Data Readouts in 2023; 2022 Financials; Raising PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/04/2022

Company Report

Pages: 4

3Q22 Financials Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/16/2022

Company Report

Pages: 5

Randomized Phase 2 Onvansertib Trial Planned; Encouraging ORR in Avastin-naive mCRC Patients; Modulating PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/08/2022

Company Report

Pages: 4

Key Catalysts Approaching; 2Q22 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/09/2022

Company Report

Pages: 4

1Q22 Financials Reported; Modulating PT to $22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

04/12/2022

Company Report

Pages: 5

AACR Presentation Takeaways; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

02/28/2022

Company Report

Pages: 4

Year-End 2021 Financial Results Reported; Modulating PT to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/19/2022

Company Report

Pages: 4

Onvansertib Efficacy Maintained in Larger Sample Size; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/24/2021

Company Report

Pages: 5

Pfizer Invests $15M; 3Q21 Financials Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CRDF

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

09/09/2021

Company Report

Pages: 4

Latest Onvansertib Phase 2 Data Encouraging, in our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/10/2021

Company Report

Pages: 4

Onvansertib CRC Update Next Month; 2Q21 Financials; Modulating PT to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cardiff Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/09/2021

Company Report

Pages: 5

Onvansertib Pancreatic Cancer Phase 2 Trial Starts Enrolling; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party